lucinactant (Surfaxin)
Jump to navigation
Jump to search
Indications
- prevention of respiratory distress syndrome in premature infants
Dosage
- administered by endotracheal tube
Adverse effects
- most common adverse effects related to use of endotracheal tube
Mechanism of action
More general terms
Additional terms
References
- ↑ FDA News Release March 6, 2012 FDA approves Surfaxin to prevent breathing disorder in premature infants http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294984.htm